Northwest Biotherapeutics develops DCVax® personalized immune therapies for solid tumor cancers. News about NWBO centers on its dendritic cell-based cancer vaccine platform, including DCVax-L for glioblastoma and DCVax-Direct for inoperable solid tumors, along with scientific presentations on next-generation dendritic cell treatments.
Company updates also cover manufacturing and treatment-logistics capacity for cell therapies, including the Sawston, UK facility, leukapheresis services, and the completed acquisition of Advent BioServices as a wholly owned subsidiary. Other recurring developments include clinical and regulatory communications, financing arrangements, capital-structure matters, operating results, and governance changes.
Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology company developing DCVax® immunotherapies, has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. The acquisition will make Advent a wholly-owned subsidiary, enabling fully integrated operations and enhanced scale-up potential.
Key transaction details include: recovery of 19 million NWBio securities previously issued to Advent, acquisition of fixed assets including cryostorage equipment, and consideration payments over two years including £1.4 million plus net accounts payable. The deal aims to consolidate operations at London and Sawston GMP facilities, focusing on manufacturing ramp-up following completion of product development work for the MAA and DCVax®-Direct program.
Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, has announced the passing of its Senior Vice President and General Counsel, Mr. Les Goldman, due to a stroke.
The company, which focuses on developing personalized immunotherapy products, has completed a 331-patient Phase III trial of DCVax-L for glioblastoma (GBM) and submitted a MAA for commercial approval in the UK. Additionally, NWBO has completed a 40-patient Phase I trial of DCVax-Direct for inoperable solid tumor cancers and plans to pursue Phase II trials this year.
Northwest Biotherapeutics (NWBO) has secured a $5 million convertible Promissory Note financing with YA II PN, , managed by Yorkville Advisors Global. The 13-month Note includes a 7% Original Issue Discount with no interest and no payments required until maturity. The Note is convertible at the holder's option at a small discount to market price, with monthly conversion limits.
Additionally, NWBO entered a standby equity subscription agreement allowing the company to require Yorkville to subscribe for up to $50 million in common shares over 24 months after the Note's repayment. The company plans to use the proceeds for general corporate purposes, including its lead product and in-licensed portfolios.
Northwest Biotherapeutics (NWBO), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, held its Annual Shareholders Meeting on June 29, 2024. Over 77% of the total shares voted, with 961.7 million votes cast out of 1.2 billion outstanding shares. Five shareholder proposals were overwhelmingly approved, including the re-election of Class I directors and the ratification of stock options and executive compensation. The company also discussed its progress and future growth opportunities, emphasizing its strong performance since the last meeting. An audio recording of the session is available on the company's website through July 7, 2024.
Northwest Biotherapeutics (OTCQB: NWBO) has secured an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP). The deal, finalized on June 12, 2024, includes five new patent families filed in 2023. These technologies, already in Phase 2 clinical trials, enhance dendritic cells (DCs) and DC-based therapies, aiming to boost immune responses and overcome resistance to checkpoint inhibitors. The clinical trials are fully grant-funded, with no expected financial or operational burden on NWBO. This license complements NWBO's existing portfolio, which was also developed by Dr. Pawel Kalinski. The terms include an upfront fee and milestone payments totaling $2.3 million, plus royalties on future sales.
Summary not available.
Summary not available.
Summary not available.
Summary not available.